Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease

Vaverkova, H.; Farnier, M.; Averna, M.; Missault, L.; Viigimaa, M.; Dong, Q.; Shah, A.; Johnson-Levonas, A.O.; Brudi, P. (2011). Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Clinical Biochemistry, 44, 627−634.10.1016/j.clinbiochem.2011.02.008.
ajakirjaartikkel
Vaverkova, H.; Farnier, M.; Averna, M.; Missault, L.; Viigimaa, M.; Dong, Q.; Shah, A.; Johnson-Levonas, A.O.; Brudi, P.
  • Inglise
Clinical Biochemistry
0009-9120
44
2011
627634
Ilmunud
1.1. Teadusartiklid, mis on kajastatud Web of Science andmebaasides Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index ja/või andmebaasis Scopus (v.a. kogumikud)
WOS

Viited terviktekstile

dx.doi.org/10.1016/j.clinbiochem.2011.02.008

Lisainfo